How is seminoma staged after radical inguinal orchiectomy using the TNM system?

Seminoma Staging After Radical Inguinal Orchiectomy

Seminoma is staged using the TNM system (8th edition AJCC) which incorporates anatomical extent (T: primary tumor, N: regional lymph nodes, M: distant metastases) and serum tumor markers (S: AFP, β-hCG, LDH) measured at least 7 days post-orchiectomy to allow proper marker kinetics evaluation. 1, 2

Critical Post-Orchiectomy Requirements

Tumor Marker Assessment

• Measure AFP, β-hCG, and LDH at minimum 7 days after radical orchiectomy in all patients regardless of preoperative values 1
• This timing is essential because β-hCG has a half-life of 1-3 days and AFP has a half-life of 5-7 days 1
• Repeat markers serially every 1-2 weeks until complete normalization, progression, or plateau if they were elevated preoperatively 1
• Any elevation of AFP indicates nonseminomatous elements and the patient must be treated as nonseminoma, regardless of histology 1

Imaging Studies

• Perform CT scans of chest, abdomen, and pelvis regardless of marker status to detect radiologically visible metastatic disease 1
• Ultrasound examination of the contralateral testicle if markers fail to normalize to exclude contralateral tumor 3

TNM Staging Components

T Stage (Primary Tumor)

• Determined by pathologic examination of the orchiectomy specimen 2
• Includes assessment of tumor size, rete testis invasion (RTI), and lymphovascular invasion (LVI) 4

N Stage (Regional Lymph Nodes)

• Based on retroperitoneal lymph node involvement on CT imaging 3
• Stage IIA: nodes <2 cm 3
• Stage IIB: nodes 2-5 cm 3
• Stage IIC: nodes >5 cm 3

M Stage (Distant Metastases)

• Assessed by chest CT and clinical examination 3

S Stage (Serum Tumor Markers)

• Critical for final staging and IGCCCG risk classification 1
• Pure seminomas are constantly AFP-negative; any AFP elevation indicates nonseminoma 1
• β-hCG can be elevated in both seminoma and nonseminoma 1
• LDH is nonspecific but serves as prognostic marker 1

Stage-Specific Clinical Implications

Clinical Stage I (No Metastases, Normal Markers)

• Surveillance is the preferred management option if resources available and patient compliant 3
• Risk stratification based on tumor size and RTI determines relapse risk (8-44% at 5 years depending on risk group) 4
• One dose of carboplatin AUC 7 if adjuvant chemotherapy considered 3
• Do not administer adjuvant treatment in patients with no risk factors 3

Stage IS (Persistently Elevated Markers)

• If markers rise or fail to normalize after orchiectomy, treat as metastatic disease 3, 1
• Inadequate decline or plateau indicates residual/metastatic disease requiring immediate systemic treatment 1

Stage IIA/B (Small Volume Retroperitoneal Disease)

• Standard treatment is 3 cycles of BEP or 4 cycles of EP if bleomycin contraindicated 3
• Radiotherapy (30 Gy stage IIA, 36 Gy stage IIB) is alternative but associated with more long-term toxicity 3

Advanced Disease

• Cisplatin-based regimen mandatory (carboplatin-based regimens inferior) 3
• Good-risk seminoma: 3 cycles BEP or 4 cycles EP 3

Common Pitfalls to Avoid

• Never measure markers before 7 days post-orchiectomy as this prevents accurate kinetics assessment 1
• Never treat elevated AFP as seminoma—this always indicates nonseminomatous elements requiring different management 1
• Do not rely on β-hCG or LDH alone to distinguish seminoma from nonseminoma 1
• Do not skip contralateral testicular ultrasound if markers fail to normalize 3
• Avoid adjuvant radiotherapy except in highly selected patients unsuitable for surveillance with contraindication to chemotherapy 3